作为一种进行性神经病变,青光眼如果不及时治疗可能会导致终身失明。新型苯基哒嗪系磺酰胺被设计为碳酸酐酶 (CA) 异构体 II 的选择性抑制剂,以寻找青光眼的有效治疗药物。随后,合成了目标抑制剂并评估了它们对胞质 CA I 和 II 的抑制作用。有趣的是,合成的分子对 CA I 的抑制效果很差,同时对 CA II 的亚纳摩尔效力较低。化合物7c具有最强的活性 (IC 50 = 0.63 nM),对 CA II 具有高选择性(是乙酰唑酰胺选择性的 605 倍)。此外,化合物7c还在青光眼体内模型中显示出显着的体内眼压降低特性。此外,利用分子对接方法在分子水平上评估了化合物7c与 CA II 的结合。
Pyridazinone derivatives and their use as agricultural fungicides
申请人:Sankyo Company Limited
公开号:US04661486A1
公开(公告)日:1987-04-28
Compounds of formula (I): ##STR1## (in which R.sup.1 and R.sup.3 are hydrogen or halogen: R.sup.2 is hydrogen, alkyl, alkoxy or halogen; R.sup.4 is hydrogen and R.sup.5 is hydroxy or alkoxy; or R.sup.4 is hydroxy and R.sup.5 is hydrogen; except that R.sup.1, R.sup.2 and R.sup.3 may not all simultaneously be hydrogen) are valuable agricultural fungicides.
Discovery of Novel Pyridazine-Tethered Sulfonamides as Carbonic Anhydrase II Inhibitors for the Management of Glaucoma
作者:Haytham O. Tawfik、Mohamed M. Saleh、Andrea Ammara、Eman F. Khaleel、Rehab Badi、Yomna T. T. Khater、Rabab A. Rasheed、Ahmed A. Attia、Salma M. Hefny、Eslam B. Elkaeed、Alessio Nocentini、Claudiu T. Supuran、Wagdy M. Eldehna、Moataz A. Shaldam
DOI:10.1021/acs.jmedchem.3c02279
日期:2024.1.25
neuropathic condition, glaucoma can cause lifelong blindness if left untreated. Novel phenylpyridazine-tethered sulfonamides were designed as selective inhibitors for carbonicanhydrase (CA) isoform II to find effective therapeutic agents for glaucoma. Subsequently, the target inhibitors were synthesized and assessed for their inhibitory action against cytosolic CA I and II. Interestingly, the synthesized
作为一种进行性神经病变,青光眼如果不及时治疗可能会导致终身失明。新型苯基哒嗪系磺酰胺被设计为碳酸酐酶 (CA) 异构体 II 的选择性抑制剂,以寻找青光眼的有效治疗药物。随后,合成了目标抑制剂并评估了它们对胞质 CA I 和 II 的抑制作用。有趣的是,合成的分子对 CA I 的抑制效果很差,同时对 CA II 的亚纳摩尔效力较低。化合物7c具有最强的活性 (IC 50 = 0.63 nM),对 CA II 具有高选择性(是乙酰唑酰胺选择性的 605 倍)。此外,化合物7c还在青光眼体内模型中显示出显着的体内眼压降低特性。此外,利用分子对接方法在分子水平上评估了化合物7c与 CA II 的结合。